Latest AB Science News & Updates
See the latest news and media coverage for AB Science. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about AB Science
In short: AB Science completed a €3.2 million private placement and secured a final agreement to renegotiate loan repayment terms with its creditors.
Company announcements
-
AB Science completes EUR 3.2 million private placement
The capital increase was subscribed by a limited number of investors. Announced on 29/04/2026.
-
AB Science announces final agreement on loan repayment renegotiation
It includes 24-month deferral of bank debt and 12-month deferral of EIB loan.
-
AB Science announces masitinib publication on medRxiv
The article evaluates long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study, showing survival benefits and preserved quality of life.
-
AB Science secures clinical trial insurance for ALS phase 3
The EUR 25 million policy covers trial costs in case of failure. AB Science voluntarily halts new patient recruitment in Europe pending strategic reorganization.
Media coverage
-
AB Science announces the successful completion of a EUR 3.2 million private placement
The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of...
-
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
PRESS RELEASEAB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial...
-
Decisions of the Annual General Meeting of Shareholders held on 24 April 2026
The Annual General Meeting of Telia Lietuva, AB (hereinafter 'the Company' or 'Telia Lietuva') shareholders was held on 24 April 2026.
-
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment...
Track AB Science and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
O-I
TMC
Agora
Applied Digital
QS
Silex
iQIYI
Kopin
Joby
Visteon
Ready Capital
Archer
Aptar
Lotus
Redwire
SmartStop
Waystar
Bristow Group
MaxLinear
Energy Fuels
Mobileye
Dakota Gold
Ubiquiti
Hudbay Minerals
Novavax
Forestar Group
Everspin
Trump Media & Technology Group
Tilde Research
Innodata
Castellum.AI
Xerox
Webull
GCT
Avis Budget Group
Groupon